You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Spiroxatrine
Spiroxatrine is a 5-HT1A antagonist. More active and selective than spiperone. Also a very potent α2C adrenergic receptor antagonist.
Technical Data for Spiroxatrine
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Spiroxatrine
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Spiroxatrine
The following data is based on the product molecular weight 379.46. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||26.35 mL||131.77 mL||263.53 mL|
|0.5 mM||5.27 mL||26.35 mL||52.71 mL|
|1 mM||2.64 mL||13.18 mL||26.35 mL|
|5 mM||0.53 mL||2.64 mL||5.27 mL|
Product Datasheets for Spiroxatrine
References for Spiroxatrine
References are publications that support the biological activity of the product.
Bylund et al (1992) Pharmacological characteristics of α2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol.Pharmacol. 42 1 PMID: 1353247
Nelson and Taylor (1986) Spiroxatrine: a selective serotonin 1A receptor antagonist. Eur.J.Pharmacol. 124 207 PMID: 3720840
Schoeffter and Hoyer (1988) Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br.J.Pharmacol. 95 975 PMID: 3207999
If you know of a relevant reference for Spiroxatrine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Spiroxatrine, Spiroxatrine supplier, Potent, α2C-adrenoceptor, alpha2C-adrenoceptor, alpah2c-adrenergic, a2c-adrenoceptor, a2c-adrenergic, antagonists, 5-HT1A, Receptors, Serotonin, Adrenergic, Alpha-2, 0631, Tocris Bioscience
1 Citation for Spiroxatrine
Citations are publications that use Tocris products. Selected citations for Spiroxatrine include:
Moura et al (2006) Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 149 1049 PMID: 17075569
Do you know of a great paper that uses Spiroxatrine from Tocris? Please let us know.
Reviews for Spiroxatrine
There are currently no reviews for this product. Be the first to review Spiroxatrine and earn rewards!
Have you used Spiroxatrine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.